AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

The European Commission has approved Tagrisso (osimertinib; AstraZeneca) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced ...

AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib ...

Sponsored By AstraZeneca Feb 10, 2025 8:00am The Top Line Pharma Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors ...

Osimertinib sales rose16% to $6.58 billion in 2024, confirming the drug's status as the leading weapon against lung cancer. Investors were excited about a potential challenger.

(RTTNews) - AstraZeneca's (AZN.L, AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been recommended for approval in the European Union for 1st-line ...